What event pauses Ghana FDA’s device evaluation?
This guide is for two groups of readers. The first is regulatory and quality staff at a foreign manufacturer of sterile single-use devices. The second is the Ghanaian applicant or local agent who received the letter. The pause is set out in section 3.1.7.2 of FDA Ghana’s Guideline for Registration of Medical Device. During evaluation, the Authority may request additional data, samples or both through a deferral letter. Once a query has been issued, “the evaluation process stops until FDA receives a written response.”1 The same section says further processing may only be made if the responses to queries issued in the same deferral letter “contain all outstanding information requested in one submission.”1
Before that point, the application has already passed intake. The guideline describes an application as hard-copy and electronic documentation plus samples and fees, and says FDA receives it only once the application fee is paid. Evaluation is first-in, first-out unless the product qualifies for expedited review. The evaluator’s report is peer-reviewed by a second evaluator, and FDA reserves the right to request any additional information needed to establish safety, quality and performance.1 A deferral letter therefore usually comes from a technical evaluation. It is not an administrative receipt.
The published text does not settle three points that buyers often assume. It does not say whether elapsed time before the query is credited when the clock restarts. It does not say how long FDA takes to review a response. And it does not describe an extension mechanism. The guideline was issued on 1 March 2016 and is still the registration guideline linked from FDA Ghana’s medical-device pages as of this review.12 Read it beside the actual letter and any later written instructions.
Which deadlines and outcomes are published?
The table below lists each published rule that can change a queried application’s status, with its source and what still needs confirming for the case. Note what each rule counts from. The twelve-month withdrawal rule runs from the date the queries were issued, not from when the applicant or manufacturer first read them.1
| Event | Published rule | Source | What to confirm for the case |
|---|---|---|---|
| Query issued in a deferral letter | Evaluation stops until FDA receives a written response.1 | Guideline s.3.1.7.2 | Letter reference, issue date and every numbered question |
| Response does not cover every item | Further processing needs all outstanding information in one submission. Failure to comply is a stated rejection ground.1 | Guideline s.3.1.7.2 | Whether every row in the worksheet has a supported answer |
| Query reissued a third time | Unsatisfactory responses after a third reissue lead to rejection.1 | Guideline s.3.1.7.2 | How many times this query has been reissued. Do not treat three as an allowance. |
| No response within 12 months of issue | Application considered withdrawn. Registration then needs a new application.1 | Guideline s.3.1.7.2 | Any due date stated in the letter or a later FDA instruction |
| Committee defers the file | The registration committee may grant, reject or defer. If required data are not provided within twelve months, the application is considered withdrawn.1 | Guideline s.3.1.7.4 | Which issue the committee raised and when |
| Refusal or conditional approval | The Chief Executive Officer informs the applicant in writing, with reasons, within thirty days. The applicant may make representations within sixty days of notification.3 | Act 851 s.118(5)–(6) | Date of notification and the stated reasons |
| Applicant withdraws | An application may be withdrawn at any time, but withdrawal does not entitle the applicant to a refund of the application fees.3 | Act 851 s.117(4) | Commercial cost of refiling versus completing the response |
| Overall processing time | Guideline: a minimum of six months, longer where queries are not addressed or not addressed adequately. Charter: fresh Class I–IV device applications within six months.15 | Guideline s.4.0; Charter (2020) | Treat both as dated published wording, not a case forecast |
Source: FDA Ghana device registration guideline (2016), Public Health Act 2012 (Act 851) and FDA Client Service Delivery Charter (2020)
The two six-month statements do not match. The guideline calls six months a minimum and says unresolved queries make the process longer. The 2020 charter, a service-standard document, lists “within 6 months” for fresh Class I–IV device applications and “within 3 months” for renewals.15 Neither document says how a query pause is counted against these figures. For planning, report both statements with their dates. Only the case correspondence can show where an individual file stands.
What must the consolidated response contain?
Start from the letter itself, not from the original dossier. Give every question its own row, even if two questions seem to need the same document. Each answer should name the exact record that supports it: report number, revision and the page or section that answers the question. A reviewer can then check the answer without searching a full technical file.
The guideline’s general submission rules are a sensible standard for the response package. Applications and supporting documents must be in English. Where a document was not originally in English, the original and a full English translation should both be submitted. The applicant is responsible for the accuracy of the translation, which must be authenticated at the nearest Ghana Embassy or by the national regulatory authority of the country where the document originated. Printed material should be legible at 12-point type or larger, with pages numbered “page x of y” and a table of contents.1 The 2016 text describes a hard copy plus an electronic copy on CD-ROM. Confirm the current submission channel and format with FDA rather than relying on that description.
| Question area | Recommended owner | Evidence to link | Done when | Published basis |
|---|---|---|---|---|
| Letter identity and timing | Ghanaian applicant or local agent | Letter reference, application reference, issue date, any stated due date, later FDA instructions | Every question has a row, an owner and a twelve-month date counted from issue | Deferral, withdrawal and rejection rules1 |
| Product, model, size and pack identity | Manufacturer regulatory lead; applicant checks | Submitted device description, the questioned variants, current label and IFU revision | Each attachment traces to the questioned model and configuration | Device details and labelling appendices1 |
| Technical substantiation | Manufacturer technical or quality owner | The relevant verification, validation or risk summary, with the exact page answering the question | The answer states what the record supports and any gap in coverage | Appendix III, sections 3.5–3.61 |
| Manufacturing site and sterilization | Manufacturer quality lead | Site addresses and activities, sterilization summary, process validation reports | Site identity matches the dossier; any discrepancy goes to FDA for clarification | Appendix III s.3.7; cGMP verification s.3.1.7.31 |
| Additional samples | Applicant confirms instructions; manufacturer supplies | FDA request, current sample schedule, variant, lot and pack details, import permission | Written quantity, recipient and shipping instructions are on file before dispatch | Act 851 s.118(3) and s.122(1); FDA import guidance34 |
| Translations and formatting | Applicant, with manufacturer source documents | Original-language document, full English translation, authentication record | Every non-English attachment has an authenticated translation | Guideline s.3.1.5–3.1.61 |
| Consolidated review | Applicant, with a named manufacturer reviewer | Response letter, attachment index, all resolved rows | A read-through of the whole letter finds an answer and record for every item | One-submission condition1 |
| Submission and follow-up | Applicant or local agent | Submitted version, transmission or receipt reference, later FDA correspondence | Submission, FDA reply and decision are logged as dated events | Written-response and decision provisions13 |
Source: Rules cited from FDA Ghana guidance and Act 851. Owner assignments and completion checks are VEMERIX editorial recommendations.
The owner and completion columns are recommendations, not FDA requirements. They exist because the one-submission rule makes the slowest row decide when the package can be sent. Every row needs a named owner who can say when it will be finished.
Who should own the manufacturer evidence and the applicant submission?
Under the guideline, either the manufacturer or an importer may apply, and the applicant is responsible for the product and all issues relating to it. A non-resident applicant must appoint a local agent, a corporate body registered in Ghana, with documentation such as a power of attorney. The local agent facilitates communication between the applicant and the Authority. After registration it also monitors the device on the market, handles recalls and supports users.1 FDA’s service page describes applications as submitted by manufacturers or local agents.2
In practice, the Ghana-side party controls the correspondence, while the manufacturer controls most of the technical records. That handoff is where mismatches can enter. The manufacturer may send a report that answers a slightly different question, or an attachment that names a different site or product. FDA’s import page lists common applicant errors that make a useful reconciliation checklist for a response package as well:4
- Manufacturer, applicant and importer names and addresses that differ from the dossier.
- Product names, and any registration or application numbers, that do not match.
- Product descriptions that are incomplete or describe a different variant.
- Attachments that belong to another product or shipment.
- The wrong form or request type for the permission actually needed.
Ask the manufacturer for one named technical reviewer for the whole package, not just for individual documents. That person should check every attachment against the questioned variant before the applicant signs the response letter.
How should a request for additional samples be handled?
Act 851 section 118(1) bars importing, distributing or selling a medical device unless it has been registered. Section 118(3) states that this does not prevent the importation of a sample for the purposes of registration. Section 122(1) separately requires a licence or permit to import a medical device.3 FDA’s import page adds that items declared as product samples must comply with the FDA sample schedule. It says FDA does not allow “trial of the market” for regulated products and will re-export or confiscate unregistered products imported in commercial quantities.4
Before dispatch, get written instructions covering the quantity, the variants and pack configuration, the recipient and the import permission route. This article does not give a sample quantity for any device type, because the device sample schedule was not available for review. The guideline does show how closely FDA can tie samples to dossier evidence. For condoms, it requires samples drawn from the batches whose certificates of analysis are in the dossier.1 That rule is specific to condoms. Still, it is a sound reason to send samples from lots and configurations that match the records being submitted.
| Event | What it is | Published basis | What it does not authorize |
|---|---|---|---|
| Registration sample shipment | Import of samples requested for evaluation | Act 851 s.118(3); sample schedule on FDA import page34 | Distribution, sale or a market trial |
| Deferral response | One written submission answering every outstanding question | Guideline s.3.1.7.21 | Any change in registration status until FDA decides |
| Commercial import | Import of a registered product by a licensed importer under a permit | Act 851 s.122(1); import guideline s.3.1 and s.4.136 | Anything outside the registered product and the permit particulars |
Source: Act 851, FDA Ghana import guidance and device registration guideline
How do you match the questioned variant to the right record?
For technical questions, start with Appendix III, the summary technical documentation. It asks for a summary of verification and validation results. For biocompatibility, it says that at a minimum, tests must be conducted on samples from the finished and sterilized device, and that significantly different materials must be characterized. It also asks for a summary of the risk analysis. Manufacturing information should include a process flow chart, a brief summary of the sterilization method and reports of process validation studies. Where several facilities are involved, the address and activities of each should be given.1
Appendix I sets label content that a sterile single-use device response may need to reconcile. It includes the manufacturer’s name and address and the manufacturing site address. It requires a batch or lot number, or a control number for Class III and IV devices, and the words “Sterile” and “for single use only” where they apply. It also requires an expiry date expressed as day, month and year, and any special storage conditions.1 If a site question arises, section 3.1.7.3 says FDA will inspect, or verify by other means, a new manufacturing site’s cGMP compliance before registration.1
The common failure is a report that is accurate but covers a different configuration, such as another size, another blister or another sterilization load. Do not attach it quietly as though it answered the question. Either state the scope difference and give a documented justification, or produce data on the questioned configuration. Our guide to matching a sample configuration to commercial EO evidence explains how that scope question works for ethylene-oxide sterilization.
Worked example: a sterile circumcision-ring response with one open row
This scenario is hypothetical. It does not describe any actual Ghana application, classification or outcome. A Ghanaian importer, acting as applicant, has filed for a single-use circumcision ring. The product configuration follows what VEMERIX publishes for its circumcision-ring Adult and Children types: ethylene-oxide sterilized and individually packed in sterile blisters.8 The deferral letter contains four questions.
| Question | Draft status | Problem found in review | Action before submitting |
|---|---|---|---|
| Q1. Biocompatibility on the finished, sterilized Children type | Open | Available report tested the Adult type only | Manufacturer prepares a documented material and process equivalence justification or new testing. Applicant asks FDA in writing whether a justification is acceptable. |
| Q2. EO sterilization validation for the blister configuration | Ready | Report covers both types in the current blister | Attach the report with the relevant pages and the product family listing marked |
| Q3. English version of a supporting test report | Ready after translation | Original report is not in English | Attach the original, a full English translation and the authentication record |
| Q4. Additional samples of both types | Waiting on instructions | Quantity and recipient not yet confirmed | Obtain written instructions and the import route. Ship lots that match the submitted records. |
Source: Illustrative scenario built on published Ghana FDA requirements
Three rows could be answered within days, but the guideline does not reward sending them early. A response that leaves Q1 unanswered fails the one-submission condition, which the guideline lists as a rejection ground.1 The applicant should hold the package and record the open question. The twelve-month date stays visible in the tracker. The commercial team should hear “query open, one technical row outstanding” rather than a revised launch date. The worksheet also shows when holding is no longer workable: if new testing cannot finish safely inside the twelve-month window, management needs to know early, while it still has choices.
How should the commercial schedule treat an open query?
Do not plan shipments around an open application. FDA’s import guideline permits only registered products to be imported, requires import permits before importation, and asks for the product registration number, brand name and generic name on a device permit. The same guideline requires imported products to arrive with at least 60% of shelf life remaining, or 80% for products with a shelf life under 24 months.6 Those requirements apply after registration, but they affect how much stock a distributor can plan to land once a decision arrives.
One public tender shows the same tension. In UNOPS tender ITB/2025/60885 for assorted medical devices in Ghana, bidders asked in January 2026 whether registration could follow award. UNOPS answered that the devices needed registration in Ghana and that both Ghana FDA registration and an international authorization were required. It added that, for equipment holding FDA approval or CE marking, the local FDA may grant an anticipated authorisation at UNOPS’ request, with the supplier still responsible for completing local registration.7 That is one buyer’s answer in one expired equipment tender. It is not a general FDA Ghana route. Separately, the 2016 guideline lists “Ministry of Health tender purposes only” among its expedited-review categories, alongside public health programmes, paediatric programmes and post-approval variations.1 Eligibility for any of these needs written confirmation for the case.
FDA’s current service page also describes market authorization through the WHO collaborative registration procedure for WHO-prequalified devices, and through reliance on decisions of other regulators.2 Those are routes into evaluation. The page does not say a reliance-based file is free of queries, so the response discipline above still applies. For a comparison with another West African market’s pre-filing checks, see our Nigeria pre-filing and query controls guide.
Pre-submission check for a Ghana deferral response
- The letter reference, application reference and issue date are recorded, along with the twelve-month date counted from issue.1
- Every question in the letter has its own row, owner and linked record. No row is marked “to follow”.
- Each attachment names the questioned model, size and pack. Any difference in report scope is stated and justified.
- Manufacturer, site, applicant and product identities match the dossier and the label.
- Every non-English document has the original, a full English translation and an authentication record.1
- Sample quantity, recipient and import route are confirmed in writing, and the sample lots match the submitted records.34
- A named manufacturer reviewer and the applicant have both checked the whole letter against the package.
- The submitted version and receipt reference are filed, and the commercial team has been told the case status rather than a forecast.
Where VEMERIX fits—and where due diligence still begins
VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. For a Ghana applicant evaluating its circumcision-ring line, the useful step is a request for specific records tied to the actual question. Send the letter reference, the exact question text, the variant and pack, and the record you think answers it.
The VEMERIX quality and regulatory information page describes the manufacturer’s quality documentation. Ghana classification, the applicant and local-agent appointment, whether a particular record covers the questioned configuration, and the FDA decision all remain specific to the case. You can send the product-document request through the contact form.
Frequently asked questions
Can the applicant send the easy answers first?
The published guideline says further processing needs all outstanding information from the same deferral letter in one submission, and names failure to comply as a rejection ground.1 Hold the package until every row is resolved, or ask FDA in writing how to handle an open item.
Can the twelve-month response period be extended?
The 2016 guideline does not describe an extension mechanism. It treats responses not submitted within twelve months of issue as withdrawal.1 If more time may be needed, ask FDA in writing, keep its reply, and plan against the published date until a written answer says otherwise.
Does a query mean the application will be rejected?
No. A deferral letter asks for additional data or samples during evaluation. At the query stage, the guideline’s rejection grounds are a response that misses the one-submission condition and unsatisfactory answers after a third reissue. The registration committee can also grant, reject or defer the file after evaluation.1 If FDA refuses registration, Act 851 requires a written decision with reasons and allows representations within sixty days.3
What if a validation report covers a different model or pack?
Say so in the response. Either give a documented justification for why the data apply to the questioned configuration, or provide data on that configuration. For biocompatibility, Appendix III expects testing on samples from the finished and sterilized device.1
Does a request for registration samples permit a commercial launch shipment?
No. Act 851 allows importation of a sample for registration, and FDA says it does not allow “trial of the market” for regulated products. Unregistered products imported in commercial quantities can be re-exported or confiscated.34
Does a reliance or WHO collaborative application avoid queries?
FDA’s service page describes both routes, but it does not say they exclude requests for additional information. The same page lists such requests among the Authority’s normal responses to applications.2 Prepare the same worksheet whichever route the application uses.
Source scope and when to recheck
Sources checked 16 November 2026. The device registration and importation guidelines are version 02 documents issued on 1 March 2016. The service charter is the 2020 second edition. The service and import pages carry no publication date.12456 No dataset of actual Ghana processing times was available, so this guide makes no elapsed-time estimate. Recheck when FDA replaces either guideline, revises the charter, sample schedule or submission channel, or sends case-specific instructions that differ from the published text.
